NCT00003951View on ClinicalTrials.gov

DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Pancreatic Cancer
Interventions
DRUG

exatecan mesylate

Trial Locations (3)

10021

Memorial Sloan-Kettering Cancer Center, New York

21287

Johns Hopkins Oncology Center, Baltimore

78284

University of Texas Health Science Center at San Antonio, San Antonio

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT00003951 - DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas | Biotech Hunter | Biotech Hunter